media – Page 58 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

KeyMed’s second breakthrough

While some pharmaceutical companies are trapped in the red sea of internal volume and cannot extricate themselves, KeyMedhas completed the second breakthrough of external volume. On November 17, KeyMedBio issued an announcement to license its autoimmune bispecific antibody pipeline CM336 to a foreign company. The transaction party is a startup company registered in the UK called Platina Medicines Ltd (PML). The form of this transaction is a NewCo form with cash and equity in parallel. It is worth mentioning that this is the second NewCo overseas expansion of KeyMedBio in 2024 after the US$185 million transaction with Belenos Biosciences in July. When KeyMedachieves a second breakthrough of external volume, what kind of surprise will it bring to the market? The BD of the second breakthrough targets the CM336 pipeline, targeting the BCMA×CD3 dual targets, which is the same target as the bispecific antibody of the BD of Epimed Bio two ...
- Source: drugdu
- 91
- November 23, 2024
Cornerstone Pharmaceuticals has reached a strategic cooperation on anti-PD-L1 monoclonal antibodies in the Middle East and Africa regions

Editor of WuXi AppTec Content Team On November 21st, Cornerstone Pharmaceuticals announced a commercial strategic partnership with Pharmalank Store. Pharmalank is a well-known pharmaceutical company headquartered in the United Arab Emirates. According to the licensing and commercialization agreement, Pharmalank will acquire the commercialization rights of Shuglimab in the Middle East and North Africa region, including Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, Algeria, Tunisia, Egypt, Morocco, Libya, and South Africa. According to the agreement, Cornerstone Pharmaceuticals will receive the down payment and subsequent registration milestone payments from Pharmarlink, as well as royalties for the net sales of Shuglimab, while Pharmarlink will be responsible for Shuglimab registration and commercialization related activities in the aforementioned regions. Cornerstone Pharmaceuticals will be responsible for the supply of Shuglimab products. According to a press release from Cornerstone Pharmaceuticals, following the strategic partnership reached with Ewopharma in Central/Eastern Europe and Switzerland in the first ...
- Source: drugdu
- 138
- November 22, 2024
Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan

November 21, 2024 07:30 Author: Du Sumin Source: Time Weekly 1 In just one week, two business development (BD) transactions with a total transaction amount exceeding 20 billion yuan have made innovative pharmaceutical company Lixin Pharmaceutical the focus of attention in the industry. On November 20th, China Biopharmaceutical (01177.HK, hereinafter referred to as “Zhongsheng Pharmaceutical”) announced that it had signed an equity investment and strategic cooperation agreement with Lixin Pharmaceutical. Accordingly, with an investment of 142 million yuan, Sinopharm will acquire 4.91% of the equity of Lixin Pharmaceutical. At the same time, it will reach strategic cooperation in Chinese Mainland on the LM-108 monoclonal antibody targeting CCR8 independently developed by Lixin Pharmaceutical, and has the right to choose multiple double antibody or ADC innovative drugs in the research pipeline of Lixin Pharmaceutical for cooperation. The specific terms will be otherwise agreed. This is the second BD transaction conducted by Lixin ...
- Source: drugdu
- 139
- November 22, 2024
Junshi Biotechnology introduces two cancer dual target fusion protein drugs

On the evening of November 19th, Junshi Biotechnology announced that it had signed a license agreement with the licensor. The licensor granted Junshi Biological the exclusive license right and sub license right to develop, manufacture, use, import, export, sell and commercialize the two double target fusion proteins in the Greater China region (including the Chinese Mainland, Hong Kong, Macao and Taiwan regions). At the same time, Junshi Biological and the licensor enjoy all the rights and interests to develop, manufacture, use, import, export, sell and commercialize one of the licensed products in the world in accordance with the equity ratio of 50%: 50%. After the signing of the license agreement, Junshi Biotechnology will make a down payment of 1.5 million US dollars (approximately 10.86 million RMB) to the licensor. Junshi Biotechnology will pay a milestone payment of no more than RMB 740 million to the licensor based on the progress ...
- Source: drugdu
- 98
- November 22, 2024
China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical

China Biopharmaceutical invested in New Pharmaceuticals with self raised funds, and reached strategic cooperation on LM-108 and many potential innovative bispecific antibodies or antibody conjugated drugs (ADC) in Chinese Mainland. According to the announcement, this agreement includes equity investment and strategic cooperation. In terms of equity investment, Lixin Pharmaceutical announced on October 18, 2024, the completion of a RMB 300 million C1 round of financing, raising funds to accelerate the development of clinical pipeline drugs and the construction of innovation platforms. According to the capital increase subscription agreement, China Biopharmaceutical, as the lead investor in this round of financing, paid RMB 142 million to Lixin Pharmaceutical and acquired 4.91% equity of Lixin Pharmaceutical after this transaction. In terms of strategic cooperation: China Biopharmaceutical and Lixin Pharmaceutical reached a strategic cooperation agreement on LM-108 in Chinese Mainland. In addition, Chinese biopharmaceuticals have the right to choose multiple bispecific antibodies or ADC ...
- Source: drugdu
- 88
- November 22, 2024
As the industry is going down, more and more pharmaceutical companies are seeking to “exit”?

In February this year, China Resources Double Crane acquired 100% of the equity of China Resources Zizhu for 3.1 billion yuan, enriched Double Crane’s specialty product line through Zizhu’s core products such as Yuting and Jin Yuting, formed a “women’s health + pediatrics” specialty product sequence, and improved the product matrix; in March, Xintian Pharmaceutical, which mainly engages in traditional Chinese medicine business, announced that it plans to acquire 85.12% of Huilun Pharmaceutical’s equity through issuing shares, expanding its business to the field of small molecule chemical drugs; in June, the domestic contrast agent leader Beilu Pharmaceutical acquired Chengde Tianyuan Pharmaceutical for 202 million yuan. 80% equity, expanding its coverage in the field of traditional Chinese medicine; in October, the plan for SinoVac (Shijiazhuang Pharmaceutical Innovation) to acquire Shijiazhuang Baike was released. SinoVac will acquire 100% equity of Shijiazhuang Baike for a total price of up to 7.6 billion yuan ...
- Source: drugdu
- 106
- November 22, 2024
Regeneron’s midlife crisis

Regeneron is a role model for the biotech community. No biotech company wants to be Regeneron. “Becoming China’s Regeneron” is the slogan of many domestic biotechs. However, such a Regeneron cannot escape its midlife crisis. The attack of opponents, the victory of Eylea generic drugs, and the successive blows of dual-antibodies have put Regeneron in an extremely delicate stage. On the one hand, with two blockbuster drugs, Regeneron has completed the transformation from biotech to big pharma. In the first half of the year, its stock price continued to rise, successfully breaking through the $100 billion threshold, and its market value reached $133.2 billion. On the other hand, although the market believes in Regeneron’s R&D and platform technology capabilities, how can a new billion-dollar blockbuster drug be so easy? And Regeneron’s highly anticipated oncology business is not as glamorous as autoimmunity and ophthalmology, and its progress is also lackluster. So ...
- Source: drugdu
- 113
- November 22, 2024
This “excellent hospital director” took the initiative to explain the problem

Eight months after leaving office, Liu Qunyou, former Party Secretary of the First People’s Hospital of Xiangtan City, Hunan Province, was investigated. According to the Xiangtan Municipal Commission for Discipline Inspection and Supervision on November 12, Liu Qunyou was suspected of serious violations of discipline and law, and took the initiative to explain the problem to the organization. He is currently undergoing disciplinary review and supervision investigation. Public information shows that Liu Qunyou is 60 years old, from Xinning, Hunan Province, with a bachelor’s degree, deputy chief physician, master’s tutor, graduated from Tongji Medical College of Huazhong University of Science and Technology, and is an in-service graduate student of Xiangya Medical College of Central South University. After graduating from university in 1986, he was assigned to Xiangtan First People’s Hospital and worked in the medical field for 38 years. In March this year, 60-year-old Liu Qunyou resigned from the post ...
- Source: drugdu
- 78
- November 22, 2024
The director of the National Medical Insurance Bureau expressed his position to promote direct settlement of medical insurance

On November 14, 2024, Zhang Ke, secretary of the Party Leadership Group and director of the National Medical Insurance Bureau, went to Xicheng District, Beijing to investigate medical insurance work. He visited the Xicheng District Medical Insurance Bureau and the Medical Insurance Affairs Management Center to learn more about the total budget management of medical insurance funds, the settlement process with designated medical institutions, and the allocation of funds. Zhang Ke said that the medical insurance department of Beijing should take the lead in trialing and innovating the settlement methods of medical insurance funds, and explore the construction of a scientific medical insurance settlement system based on direct settlement, instant settlement, and synchronous settlement. It is necessary to actively promote direct settlement and instant settlement between medical insurance and hospitals, pharmaceutical companies, and equipment and consumables manufacturers. For a long time, the long collection cycle has imposed a heavy financial ...
- Source: drugdu
- 66
- November 22, 2024
【EXPERT Q&A】How to check the drug registration standards? Where do you find it?

Drugdu.com expert’s response: The inquiry of drug registration standards typically involves multiple levels and channels. Here are some suggested methods and avenues for inquiry: Ⅰ. Methods of Inquiry Official Website Inquiry: (1) CDE (National Medical Products Administration’s Center for Drug Evaluation) Website: CDE is responsible for the evaluation of drug registration applications, and its website usually publishes information related to drug registration. Through sections such as “Information Disclosure” or “Application Directory Browsing” on the CDE website, you can inquire about the overall acceptance status of drug registration applications and the progress of evaluation and approval. Additionally, CDE provides specific inquiry services for the acceptance, evaluation, and approval progress of drug registration applications, and applicants can inquire through the “Applicant’s Window” section. (2) National Medical Products Administration Website: The National Medical Products Administration is the authoritative agency for drug registration approval, and its website also publishes information and policies related to ...
- Source: drugdu
- 122
- November 22, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.